Skip to main content
. Author manuscript; available in PMC: 2022 Sep 7.
Published in final edited form as: Lancet Infect Dis. 2021 Sep 13;22(1):97–109. doi: 10.1016/S1473-3099(21)00125-0

Figure 3. Solicited AEs after vaccination in stage 1 and stage 2 participants.

Figure 3

Solicited local (A) and systemic (B) AEs after the first dose, and solicited local (C) and systemic (D) AEs after the second dose. Solicited AEs were observed during the period of 7 days after vaccination. Grade 3 solicited AEs were severe AEs requiring medical attention, but which were not immediately life-threatening. Ad26.ZEBOV=adenovirus type 26 vector-based vaccine encoding the Ebola virus glycoprotein. MenACWY=meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine. MVA-BN-Filo=modified vaccinia Ankara vector-based vaccine, encoding glycoproteins from the Ebola virus, Sudan virus, and Marburg virus, and the nucleoprotein from the Tai Forest virus.